Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry.
Swaminathan AC, Hellkamp AS, Neely ML, Bender S, Paoletti L, White ES, Palmer SM, Whelan TPM, Dilling DF; Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry investigators. Swaminathan AC, et al. Among authors: dilling df. Ann Am Thorac Soc. 2022 Jun;19(6):981-990. doi: 10.1513/AnnalsATS.202105-589OC. Ann Am Thorac Soc. 2022. PMID: 35073248 Free PMC article.
A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis.
Lu C, Lee HS, Pappas GP, Dilling DF, Burger CD, Shifren A, Veeraraghavan S, Chapman JT, Parambil J, Ruoss SJ, Young LR, Hammes SR, Kopras EJ, Roads T, Krischer JP, McCormack FX; Trial of an Aromatase Inhibitor in Lymphangioleiomyomatosis Group. Lu C, et al. Among authors: dilling df. Ann Am Thorac Soc. 2017 Jun;14(6):919-928. doi: 10.1513/AnnalsATS.201610-824OC. Ann Am Thorac Soc. 2017. PMID: 28570161 Clinical Trial.
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD Trial Investigators. Flaherty KR, et al. N Engl J Med. 2019 Oct 31;381(18):1718-1727. doi: 10.1056/NEJMoa1908681. Epub 2019 Sep 29. N Engl J Med. 2019. PMID: 31566307 Clinical Trial.
Donation after circulatory death in lung transplantation-five-year follow-up from ISHLT Registry.
Van Raemdonck D, Keshavjee S, Levvey B, Cherikh WS, Snell G, Erasmus M, Simon A, Glanville AR, Clark S, D'Ovidio F, Catarino P, McCurry K, Hertz MI, Venkateswaran R, Hopkins P, Inci I, Walia R, Kreisel D, Mascaro J, Dilling DF, Camp P, Mason D, Musk M, Burch M, Fisher A, Yusen RD, Stehlik J, Cypel M; International Society for Heart and Lung Transplantation. Van Raemdonck D, et al. Among authors: dilling df. J Heart Lung Transplant. 2019 Dec;38(12):1235-1245. doi: 10.1016/j.healun.2019.09.007. J Heart Lung Transplant. 2019. PMID: 31777330
Associations between Patient-reported Outcomes and Death or Lung Transplant in Idiopathic Pulmonary Fibrosis. Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry.
Case AH, Hellkamp AS, Neely ML, Bender S, Dilling DF, Gulati M, Hotchkin DL, Huie TJ, Lancaster L, Snyder LD, Conoscenti CS, Palmer SM. Case AH, et al. Among authors: dilling df. Ann Am Thorac Soc. 2020 Jun;17(6):699-705. doi: 10.1513/AnnalsATS.201906-437OC. Ann Am Thorac Soc. 2020. PMID: 32040340 Free PMC article.
Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort.
Todd JL, Vinisko R, Liu Y, Neely ML, Overton R, Flaherty KR, Noth I, Newby LK, Lasky JA, Olman MA, Hesslinger C, Leonard TB, Palmer SM, Belperio JA; IPF-PRO Registry investigators. Todd JL, et al. BMC Pulm Med. 2020 Mar 14;20(1):64. doi: 10.1186/s12890-020-1103-4. BMC Pulm Med. 2020. PMID: 32171287 Free PMC article.
61 results